Cisen Pharmaceutical Co Ltd (603367) - Net Assets
Based on the latest financial reports, Cisen Pharmaceutical Co Ltd (603367) has net assets worth CN¥6.19 Billion CNY (≈ $906.39 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.62 Billion ≈ $1.12 Billion USD) and total liabilities (CN¥1.43 Billion ≈ $208.78 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Cisen Pharmaceutical Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.19 Billion |
| % of Total Assets | 81.28% |
| Annual Growth Rate | 12.17% |
| 5-Year Change | 24.68% |
| 10-Year Change | 185.27% |
| Growth Volatility | 14.59 |
Cisen Pharmaceutical Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Cisen Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 603367 asset base for the complete picture of this company's asset base.
Annual Net Assets for Cisen Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual net assets of Cisen Pharmaceutical Co Ltd from 2011 to 2024. For live valuation and market cap data, see Cisen Pharmaceutical Co Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.99 Billion ≈ $876.08 Million |
+3.82% |
| 2023-12-31 | CN¥5.77 Billion ≈ $843.81 Million |
+7.67% |
| 2022-12-31 | CN¥5.36 Billion ≈ $783.73 Million |
+5.94% |
| 2021-12-31 | CN¥5.06 Billion ≈ $739.79 Million |
+5.28% |
| 2020-12-31 | CN¥4.80 Billion ≈ $702.68 Million |
+4.99% |
| 2019-12-31 | CN¥4.57 Billion ≈ $669.29 Million |
+10.08% |
| 2018-12-31 | CN¥4.15 Billion ≈ $608.01 Million |
+11.56% |
| 2017-12-31 | CN¥3.72 Billion ≈ $544.98 Million |
+62.03% |
| 2016-12-31 | CN¥2.30 Billion ≈ $336.34 Million |
+9.52% |
| 2015-12-31 | CN¥2.10 Billion ≈ $307.11 Million |
+10.39% |
| 2014-12-31 | CN¥1.90 Billion ≈ $278.19 Million |
+10.12% |
| 2013-12-31 | CN¥1.73 Billion ≈ $252.63 Million |
+8.95% |
| 2012-12-31 | CN¥1.58 Billion ≈ $231.88 Million |
+17.86% |
| 2011-12-31 | CN¥1.34 Billion ≈ $196.74 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cisen Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3001.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.34 Billion | 56.20% |
| Common Stock | CN¥452.75 Million | 7.61% |
| Other Comprehensive Income | CN¥253.41 Million | 4.26% |
| Other Components | CN¥1.90 Billion | 31.93% |
| Total Equity | CN¥5.95 Billion | 100.00% |
Cisen Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Cisen Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Altareit
PA:AREIT
|
$1.04 Billion |
|
Jiangsu LiXing General Steel Ball Co Ltd
SHE:300421
|
$1.04 Billion |
|
Chengdu Guibao Science Tech
SHE:300019
|
$1.04 Billion |
|
Episil-Precision Inc
TW:3016
|
$1.04 Billion |
|
JC Finance & Tax Interconnect Holdings Ltd
SHE:002530
|
$1.04 Billion |
|
ARB Corporation Ltd
AU:ARB
|
$1.04 Billion |
|
Helix Energy Solutions Group Inc
NYSE:HLX
|
$1.04 Billion |
|
CTCI Corp
TW:9933
|
$1.04 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cisen Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,727,355,807 to 5,949,558,724, a change of 222,202,917 (3.9%).
- Net income of 508,906,200 contributed positively to equity growth.
- Dividend payments of 304,557,606 reduced retained earnings.
- Other comprehensive income increased equity by 11,262,956.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥508.91 Million | +8.55% |
| Dividends Paid | CN¥304.56 Million | -5.12% |
| Other Comprehensive Income | CN¥11.26 Million | +0.19% |
| Other Changes | CN¥6.59 Million | +0.11% |
| Total Change | CN¥- | 3.88% |
Book Value vs Market Value Analysis
This analysis compares Cisen Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.20x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.15x to 1.20x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥3.79 | CN¥15.70 | x |
| 2012-12-31 | CN¥4.46 | CN¥15.70 | x |
| 2013-12-31 | CN¥4.86 | CN¥15.70 | x |
| 2014-12-31 | CN¥5.35 | CN¥15.70 | x |
| 2015-12-31 | CN¥5.95 | CN¥15.70 | x |
| 2016-12-31 | CN¥6.51 | CN¥15.70 | x |
| 2017-12-31 | CN¥9.83 | CN¥15.70 | x |
| 2018-12-31 | CN¥9.16 | CN¥15.70 | x |
| 2019-12-31 | CN¥10.09 | CN¥15.70 | x |
| 2020-12-31 | CN¥10.61 | CN¥15.70 | x |
| 2021-12-31 | CN¥11.24 | CN¥15.70 | x |
| 2022-12-31 | CN¥11.81 | CN¥15.70 | x |
| 2023-12-31 | CN¥12.63 | CN¥15.70 | x |
| 2024-12-31 | CN¥13.09 | CN¥15.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cisen Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.55%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.78%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.27x
- Recent ROE (8.55%) is below the historical average (11.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 17.62% | 15.47% | 0.97x | 1.17x | CN¥102.48 Million |
| 2012 | 17.91% | 13.84% | 1.00x | 1.30x | CN¥125.39 Million |
| 2013 | 12.08% | 9.44% | 0.93x | 1.37x | CN¥35.83 Million |
| 2014 | 11.59% | 9.22% | 0.89x | 1.42x | CN¥30.26 Million |
| 2015 | 11.77% | 9.89% | 0.82x | 1.45x | CN¥37.08 Million |
| 2016 | 10.76% | 9.63% | 0.78x | 1.43x | CN¥17.33 Million |
| 2017 | 9.86% | 12.40% | 0.62x | 1.27x | CN¥-5.06 Million |
| 2018 | 12.12% | 13.22% | 0.73x | 1.26x | CN¥88.15 Million |
| 2019 | 11.25% | 12.51% | 0.74x | 1.21x | CN¥57.32 Million |
| 2020 | 9.14% | 11.94% | 0.60x | 1.28x | CN¥-41.31 Million |
| 2021 | 6.61% | 8.83% | 0.59x | 1.26x | CN¥-171.34 Million |
| 2022 | 6.56% | 8.61% | 0.60x | 1.28x | CN¥-183.26 Million |
| 2023 | 9.10% | 11.68% | 0.61x | 1.28x | CN¥-51.40 Million |
| 2024 | 8.55% | 12.78% | 0.53x | 1.27x | CN¥-86.05 Million |
Industry Comparison
This section compares Cisen Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,691,234,838
- Average return on equity (ROE) among peers: 6.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cisen Pharmaceutical Co Ltd (603367) | CN¥6.19 Billion | 17.62% | 0.23x | $1.04 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $903.62 Million | 4.28% | 2.45x | $1.16 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.22 Billion | 5.35% | 1.27x | $441.99 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $9.87 Billion | 20.71% | 0.25x | $5.01 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.80 Billion |
| Wedge Industrial Co Ltd (000534) | $1.15 Billion | 11.42% | 1.59x | $3.04 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $9.03 Billion | 25.71% | 0.43x | $13.75 Billion |
| Hainan Haiyao Co Ltd (000566) | $275.57 Million | 17.28% | 1.12x | $947.33 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $231.22 Million | -38.13% | 1.23x | $389.67 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $4.29 Billion | 2.31% | 2.07x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.32 Billion |
About Cisen Pharmaceutical Co Ltd
Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products in China and internationally. The company's chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infe… Read more